La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Syngene International Crescita futura

Future criteri di controllo 3/6

Syngene International prevede che gli utili e i ricavi cresceranno rispettivamente di 18.1% e 14.6% all'anno. Si prevede che l'EPS crescerà di 17.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.6% in 3 anni.

Informazioni chiave

18.1%

Tasso di crescita degli utili

17.2%

Tasso di crescita dell'EPS

Life Sciences crescita degli utili	22.4%
Tasso di crescita dei ricavi	14.6%
Rendimento futuro del capitale proprio	13.6%
Copertura analitica	Good
Ultimo aggiornamento	26 Jul 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

Jul 16

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Mar 28

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Apr 28

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Apr 06

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Jan 04

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Dec 08

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Aug 28

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Aug 10

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

May 10

Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?

Feb 02

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Nov 26

Here's Why Syngene International (NSE:SYNGENE) Can Manage Its Debt Responsibly

Sep 21

Here's Why I Think Syngene International (NSE:SYNGENE) Is An Interesting Stock

Aug 06

Previsioni di crescita degli utili e dei ricavi

NSEI:SYNGENE - Stime future degli analisti e dati finanziari passati (INR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	51,176	7,889	4,248	N/A	6
3/31/2026	45,967	7,220	3,807	N/A	9
3/31/2025	38,228	5,642	2,806	N/A	8
6/30/2024	34,702	4,923	N/A	N/A	N/A
3/31/2024	34,886	5,100	5,313	10,421	N/A
12/31/2023	35,661	5,002	N/A	N/A	N/A
9/30/2023	34,985	4,984	4,706	10,290	N/A
6/30/2023	33,565	4,839	N/A	N/A	N/A
3/31/2023	31,929	4,644	3,052	8,235	N/A
12/31/2022	29,566	4,334	N/A	N/A	N/A
9/30/2022	28,121	4,277	1,083	5,898	N/A
6/30/2022	26,542	3,924	N/A	N/A	N/A
3/31/2022	26,042	3,958	1,051	5,806	N/A
12/31/2021	25,047	4,086	N/A	N/A	N/A
9/30/2021	24,478	4,068	2,102	6,566	N/A
6/30/2021	23,572	4,242	N/A	N/A	N/A
3/31/2021	21,843	4,049	2,547	7,012	N/A
12/31/2020	21,330	3,645	N/A	N/A	N/A
9/30/2020	20,676	3,541	1,217	6,318	N/A
6/30/2020	20,126	3,981	N/A	N/A	N/A
3/31/2020	20,119	4,121	340	6,771	N/A
12/31/2019	19,385	3,920	N/A	N/A	N/A
9/30/2019	18,865	3,872	1,257	7,549	N/A
6/30/2019	18,405	3,374	N/A	N/A	N/A
3/31/2019	18,256	3,316	471	6,304	N/A
12/31/2018	17,008	3,160	N/A	N/A	N/A
9/30/2018	16,214	3,110	N/A	N/A	N/A
6/30/2018	15,380	3,096	N/A	N/A	N/A
3/31/2018	14,231	3,054	N/A	4,462	N/A
12/31/2017	13,053	2,993	N/A	N/A	N/A
9/30/2017	12,497	2,917	N/A	N/A	N/A
6/30/2017	12,175	2,895	N/A	N/A	N/A
3/31/2017	12,009	2,873	N/A	3,977	N/A
12/31/2016	12,411	2,682	N/A	N/A	N/A
9/30/2016	11,894	2,606	N/A	N/A	N/A
6/30/2016	11,479	2,344	N/A	N/A	N/A
3/31/2016	11,070	2,408	N/A	3,081	N/A
12/31/2015	10,235	2,103	N/A	N/A	N/A
9/30/2015	9,713	1,964	N/A	N/A	N/A
6/30/2015	9,017	1,843	N/A	N/A	N/A
3/31/2015	8,599	1,750	N/A	185	N/A
3/31/2014	6,995	1,339	N/A	2,995	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di SYNGENE ( 18.1% all'anno) è superiore al tasso di risparmio ( 6.7% ).

Guadagni vs Mercato: Si prevede che gli utili di SYNGENE ( 18.1% all'anno) cresceranno più rapidamente del mercato Indian ( 16.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di SYNGENE cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di SYNGENE ( 14.6% all'anno) crescerà più rapidamente del mercato Indian ( 10% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di SYNGENE ( 14.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di SYNGENE sarà basso tra 3 anni ( 13.6 %).

Syngene International Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 8.9% to ₹808

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Syngene International Limited Provides Earnings Guidance for the Year 2022

Recent updates

MD, CEO & Executive Director recently sold ₹115m worth of stock

Head of Formulations Development recently sold ₹9.6m worth of stock

Syngene International Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited Approves for the Financial Year Ended March 31, 2024

Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited to Report Q1, 2025 Results on Jul 24, 2024

New minor risk - Insider selling

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹4.9m worth of stock

Dividend of ₹1.25 announced

Syngene International Limited, Annual General Meeting, Jul 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Recommends Final Dividend for the Financial Year 2024

Syngene International Limited to Report Q4, 2024 Results on Apr 24, 2024

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Head of IT recently sold ₹1.5m worth of stock

Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024

Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Insider recently sold ₹9.9m worth of stock

Syngene International Limited to Report Q3, 2024 Results on Jan 25, 2024

Head of Investor Relations recently sold ₹1.7m worth of stock

Head of Investor Relations recently sold ₹1.8m worth of stock

Is Syngene International (NSE:SYNGENE) A Risky Investment?

Insider recently sold ₹7.1m worth of stock

Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024

Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director

Second quarter 2024 earnings released: EPS: ₹2.90 (vs ₹2.55 in 2Q 2023)

Syngene International Limited Announces Retirement of Joydeep Kant as Sr. Vice President - Development Services, Effective October 31, 2023

Syngene International Limited to Report Q2, 2024 Results on Oct 17, 2023

Chief Financial Officer recently sold ₹57m worth of stock

Insider recently sold ₹2.4m worth of stock

Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

Price target increased by 8.9% to ₹808

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of ₹1.25 per share at 0.1% yield

Insider recently sold ₹2.3m worth of stock

MD, CEO & Executive Director recently sold ₹166m worth of stock

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Insider recently sold ₹2.1m worth of stock

Insider recently sold ₹4.6m worth of stock

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.9m worth of stock

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Third quarter 2023 earnings released: EPS: ₹2.74 (vs ₹2.57 in 3Q 2022)

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.4m worth of stock

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.0m worth of stock

Insider recently sold ₹7.8m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹4.3m worth of stock

Syngene International Limited Provides Earnings Guidance for the Year 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹1.1m worth of stock

MD, CEO & Executive Director recently sold ₹20m worth of stock

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Chief Human Resources Officer recently sold ₹13m worth of stock

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Insider recently sold ₹4.0m worth of stock

Syngene International Limited Approves the Additional Special Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited to Report Q3, 2023 Results on Jan 23, 2023

Upcoming dividend of ₹1.00 per share